Arvinas (ARVN) Return on Capital Employed (2018 - 2026)
Arvinas (ARVN) recorded quarterly Return on Capital Employed of 44.76% in Q1 2026, down 141.21% quarter-over-quarter from 18.56% in Q4 2025, and down 3327.0% on a YoY basis from 1.39% in Q1 2025.
Arvinas (ARVN) Return on Capital Employed (2018 - 2026) Analysis & Trends
Arvinas' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 44.76% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3327.0% year-over-year to 44.76%; the TTM figure through Mar 2026 stood at 44.76% (down 3327.0% YoY), while the FY2025 annual figure was 15.55%, up 1029.0% from the prior year.
- Return on Capital Employed was 44.76% for Q1 2026 at Arvinas, down from 18.56% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.49% in Q1 2025 to a low of 44.76% in Q1 2026.
- Historically, Return on Capital Employed has averaged 28.42% across 5 years, with a median of 27.83% in 2024.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 2753 bps in 2025, then slumped 3327 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 26.16% in 2022, then sank by 66 bps to 43.44% in 2023, then soared by 36 bps to 27.83% in 2024, then soared by 33 bps to 18.56% in 2025, then slumped by 141 bps to 44.76% in 2026.
- The last three Return on Capital Employed figures came in at 44.76% (Q1 2026), 18.56% (Q4 2025), and 13.95% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -44.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.76% |
| Dec 31, 2025 | -18.56% |
| Sep 30, 2025 | -13.95% |
| Jun 30, 2025 | -14.87% |
| Mar 31, 2025 | -11.49% |
| Dec 31, 2024 | -27.83% |
| Sep 30, 2024 | -37.72% |
| Jun 30, 2024 | -41.27% |
| Mar 31, 2024 | -39.02% |
| Dec 31, 2023 | -43.44% |
| Sep 30, 2023 | -41.37% |
| Jun 30, 2023 | -36.73% |
| Mar 31, 2023 | -31.23% |
| Dec 31, 2022 | -26.16% |
| Sep 30, 2022 | -20.89% |
| Jun 30, 2022 | -18.05% |
| Mar 31, 2022 | -15.76% |
| Dec 31, 2021 | -14.15% |
| Sep 30, 2021 | -19.12% |
| Jun 30, 2021 | -26.49% |